Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation
NCT02704858Phase 2Active, not recruiting
- Sponsor
- NeOnc Technologies Holdings, Inc.
- Start
- Aug 2017
- Primary completion
- Nov 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Inhalation Devices, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of NEO100-02 in glioblastoma multiforme (GBM) and astrocytoma (2 arms), sponsored by NeOnc Technologies Holdings, Inc. Primary endpoints: Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment at 6 months and Number of Participants Who Are Alive Each Month For 6 Months. Started Aug 2017; status: active, not recruiting.
02
Drugs
NEO100-02
03
Conditions
glioblastoma multiforme (GBM)astrocytoma
Beyond the preview
Go deeper on NCT02704858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02704858.